Vabicaserin
serotonergic · positive symptoms (comparable to olanzapine in one trial) class / serotonergicspec sheet6 rows
Vabicaserin was Wyeth's, and later Pfizer's (after the 2009 acquisition), selective 5-HT2C receptor agonist built on a completely different premise than dopamine-blocking antipsychotics: activating 5-HT2C receptors indirectly dampens mesolimbic dopamine release, offering a theoretically cleaner route to antipsychotic effect without the metabolic baggage. In a 6-week Phase II trial in acute schizophrenia, vabicaserin reduced psychotic symptoms about as well as olanzapine, a well-established comparator, and crucially did so without olanzapine's characteristic weight gain. Despite that clean efficacy-versus-side-effect trade, Pfizer discontinued the schizophrenia and obesity programs; later quantitative systems pharmacology modeling suggested the clinical benefit ceiling for a pure 5-HT2C agonist approach was modest, which likely reinforced the decision to walk away rather than fund the expensive Phase III program needed to confirm it.
- reduced positive symptoms comparably to olanzapine in a head-to-head Phase II trial
- did not cause the weight gain associated with olanzapine
- offered a non-dopaminergic mechanism, sidestepping classic antipsychotic motor side effects
- gastrointestinal complaints reported in trial participants
- development discontinued before Phase III could confirm durability of effect
- modeling later suggested a modest efficacy ceiling for the mechanism
- Vabicaserin beat olanzapine's weight-gain problem in its own head-to-head trial, which is part of why its shelving is considered one of the more puzzling business decisions in the antipsychotic pipeline of the 2010s.
Mechanism
Selective 5-HT2C receptor (EC50 around 8 nM); reduces mesolimbic release indirectly rather than blocking dopamine receptors directly.
Safetyrisks and cautions, not medical advice
Weight is the number that made this trial interesting. Over six weeks in 314 hospitalized patients, olanzapine produced its usual weight gain and vabicaserin at 200 mg or 400 mg a day did not, with no significant safety signals reported at either dose. That is an unusually favorable result for an antipsychotic candidate and it did not save the program. Two caveats belong beside it: six weeks is short, and the higher 400 mg dose performed worse on efficacy than the lower one, the sort of inverted dose response that usually means something is happening a short trial cannot see.
History
Developed by Wyeth, continued by Pfizer after 2009; a Phase II trial in acute schizophrenia showed efficacy comparable to olanzapine without weight gain, but Pfizer discontinued development for both schizophrenia and obesity indications afterward.
Subjective profileweighing the evidence above
One of the few antipsychotic candidates that actually matched a marketed comparator head-to-head in a trial, and it still got shelved on a business call rather than a failed one.
Resources
This entry is here for reference.
Research
1 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
Was vabicaserin ever approved?
No, Pfizer discontinued its development for both schizophrenia and obesity after Phase II, despite a favorable efficacy and weight-neutrality profile.
How does a serotonin drug treat psychosis without touching dopamine receptors directly?
5-HT2C receptors sit on GABA interneurons that regulate mesolimbic dopamine release; agonizing them indirectly dials down dopamine signaling in the pathways linked to psychosis, without blocking dopamine receptors outright.
Adverse effects
- gastrointestinal complaints reported in trial participants
- development discontinued before Phase III could confirm durability of effect
- modeling later suggested a modest efficacy ceiling for the mechanism